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Abstract
We evaluated the therapeutic effect of secretory phospholipase
A2 (sPLA2)-inhibitory peptide at a cellular level on joint erosion,
cartilage destruction, and synovitis in the human tumor necrosis
factor (TNF) transgenic mouse model of arthritis. Tg197 mice (N
= 18) or wild-type (N = 10) mice at 4 weeks of age were given
intraperitoneal doses (7.5 mg/kg) of a selective sPLA2 inhibitory
peptide, P-NT.II, or a scrambled P-NT.II (negative control), three
times a week for 4 weeks. Untreated Tg197 mice (N = 10) were
included as controls. Pathogenesis was monitored weekly for 4
weeks by use of an arthritis score and histologic examinations.
Histopathologic analysis revealed a significant reduction after P-
NT.II treatment in synovitis, bone erosion, and cartilage
destruction in particular. Conspicuous ultrastructural alterations
seen in articular chondrocytes (vacuolated cytoplasm and loss
of nuclei) and synoviocytes (disintegrating nuclei and vacuoles,
synovial adhesions) of untreated or scrambled-P-NT.II-treated
Tg197 mice were absent in the P-NT.II-treated Tg197 group.
Histologic scoring and ultrastructural evidence suggest that the
chondrocyte appears to be the target cell mainly protected by
the peptide during arthritis progression in the TNF transgenic
mouse model. This is the first time ultrastructural evaluation of
this model has been presented. High levels of circulating sPLA2
detected in untreated Tg197 mice at age 8 weeks of age were
reduced to basal levels by the peptide treatment. Attenuation of
lipopolysaccharide- and TNF-induced release of prostaglandin
E2 from cultured macrophage cells by P-NT.II suggests that the
peptide may influence the prostaglandin-mediated inflammatory
response in rheumatoid arthritis by limiting the bioavailability of
arachidonic acid through sPLA2 inhibition.
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Introduction
Secretory phospholipase A2 (sPLA2) is a key enzyme in the
production of diverse mediators of inflammatory and related
conditions [1]. Because of the crucial role it plays in inflam-
matory diseases such as rheumatoid arthritis (RA) [2],
sPLA2 is referred to as inflammatory PLA2 [3]. High levels
of sPLA2 have been found in synovial tissues and fluid from
patients with RA [2,4]. Purified synovial PLA2 can elicit an
inflammatory arthritogenic response when injected into the
joint space of healthy rabbits and rats [5,6]. It has been
reported that sPLA2 expression parallels the severity of the
inflammatory process with lack of enhancement of
cytosolic phospholipase A2 (cPLA2) mRNA in an adjuvant
arthritis model, thus indicating the pathogenic role played
by sPLA2 [7]. Colocalization studies using primary synovial
fibroblasts from RA patients have also suggested sPLA2 as
a critical modulator of cytokine-mediated synovial inflamma-
tion in RA [8]. As a result of its important role in the inflam-
matory response, inhibition of sPLA2 is a target for the
treatment of inflammatory diseases. Inhibition of sPLA2
AA = arachidonic acid; ANOVA = analysis of variance; AS = arthritis score; cPLA2 = cytosolic phospholipase A2; DMSO = dimethyl sulfoxide; HS = 
histopathologic score; LPS = lipopolysaccharide; PGE = prostaglandin E; PIP = phospholipase inhibitor from python; RA = rheumatoid arthritis; r-
ER = rough endoplasmic reticulum; SEM = standard error of the mean; sPLA2 = secretory phospholipase A2; Tg = transgenic; TNF = tumor necrosis 
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could result in suppression of several classes of proinflam-
matory lipids such as prostaglandins, leukotrienes, platelet-
activating factor, and lysophospholipid [1].
Elevated levels of circulating sPLA2 are usually associated
with high blood levels of proinflammatory cytokines [9],
which are used as an indicator of the extent of systemic
inflammation [10,11]. sPLA2 has been shown to activate
the production of proinflammatory cytokines in blood and
synovial fluid monocytes [12], suggesting that the two can
cooperate to promote inflammation by enhancing each
other's secretion. sPLA2 may act on the cells stimulated
with such cytokines, leading to augmentation of the inflam-
matory responses. The fact that cotransgenic sPLA2 and
tumor necrosis factor α (TNF-α) mice show more extensive
swelling than TNF-α transgenic mice [13] may be evidence
in support of a possible synergism between sPLA2 and
TNF. Hence, inhibition of sPLA2 may further help to sup-
press inflammation in RA by blocking the formation of proin-
flammatory cytokines.
A significant reduction of the inflammatory response has
been reported in animals injected with natural or synthetic
sPLA2 inhibitors [14,15]. Two families of endogenous pro-
teins, namely lipocortins and uteroglobin, have been shown
to possess anti-inflammatory properties due to their ability
to inhibit sPLA2. Synthetic peptides called antiflammins
derived from these proteins are one of the most potent
classes of anti-inflammatory agents identified to date [16].
A recombinant protein termed PIP (phospholipase inhibitor
from python), which we have expressed from the liver of a
nonvenomous snake, Python reticulatus [17], exhibits in
vivo anti-inflammatory activity that correlates well with its in
vitro inhibitory potency towards sPLA2. In a clinically rele-
vant model of postsurgical peritoneal adhesion, the peptide
analog P-PB.III, which has a fragment of an anti-inflamma-
tory protein PIP included in its sequence, exhibits stronger
in vivo anti-inflammatory activity than that displayed by anti-
flammin [18]. Further screening of the PIP amino acid
sequence provides us with a new peptide with improved
potency. This new 17-mer peptide
56LGRVDIHVWDGVYIRGR72  is a selective inhibitor of
human sPLA2-IIA, with an amino acid sequence corre-
sponding to residues 56–72 of the native protein PIP. It sig-
nificantly reduces high levels of sPLA2 detected in rat
hippocampal homogenates after intracerebroventricular
injections of a neurotoxin, kainic acid [19]. These findings
establish that peptides or recombinant proteins that inhibit
sPLA2, or their peptide derivatives, are highly attractive can-
didates for clinical development as anti-inflammatory
agents.
The present study was designed to investigate the effect of
a selective sPLA2-inhibitory peptide, P-NT.II, on ultrastruc-
tural changes of ankle-joint synovitis, cartilage degradation,
and bone erosion in the Tg197 TNF transgenic mouse
model of arthritis [20], and to assess the effects of peptide
intervention on the clinical and histologic indices of RA.
Materials and methods
Animals
The generation and characterization of Tg197 human TNF
transgenic mice have been previously described [20].
Tg197 mice generated on CBA × C57BL/6 genetic back-
grounds and littermate controls were bred and maintained
at the animal facilities of the Biomedical Sciences
Research Center, Alexander Fleming, Athens, Greece,
under specific-pathogen-free conditions. All of the Tg197
mice typically developed polyarthritis 3–4 weeks after birth,
whereas nontransgenic (wild-type) mice remained normal.
Mice were given conventional oral food and water ad libi-
tum. All procedures involving animals were in compliance
with the Declaration of Helsinki principles.
Experimental protocol
A total of 44 weight-matched mice (34 Tg197 and 10 non-
transgenic wild-type littermates) were divided into six
groups for subsequent gross observations and histopatho-
logic analyses – untreated Tg197 group (N = 10), P-NT.II-
treated Tg197 group (N = 18), scrambled-P-NT.II-treated
Tg197 group (N = 6), P-NT.II-treated wild-type group (N =
4), scrambled-P-NT.II-treated wild-type group (N = 4), and
Tg197 baseline group – just before the treatment at 4
weeks of age (N = 4). Nontransgenic mice were given the
same dose of P-NT.II or scrambled P-NT.II, and the same
regimen of treatment, as the Tg197 mice.
Peptide synthesis and administration
P-NT.II (test peptide) and the scrambled P-NT.II (negative
control peptide) were synthesized using the solid-phase
method with 9-fluorenylmethoxy carbonyl chemistry and
were purified and validated as described elsewhere [18].
They were stored lyophilized at -20°C in sealed tubes and
were dissolved freshly before use in 0.1% dimethyl sulfox-
ide (DMSO). Each Tg197 or wild-type mouse was given
intraperitoneal injections of P-NT.II or the scrambled P-NT.II
(7.5 mg/kg) in 50 µl of vehicle (0.1% final DMSO concen-
tration), three times a week for 4 weeks (i.e. from age 4–8
weeks).
Clinical assessment
This was done by gross observations based on body-
weight measurements and arthritis scoring, which were
done twice weekly from 4 weeks (baseline) to 8 weeks of
age (end of the study), after which all the animals were
killed by CO2 inhalation. The level of severity of clinical
arthritis was evaluated based on an arthritis score (AS)
taken on both ankle joints. Average scores on a scale of 0–
3 were used; 1 = mild arthritis (joint swelling); 2 = moder-
ate arthritis (severe joint swelling and deformation, no gripAvailable online http://arthritis-research.com/content/6/3/R282
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strength); 3 = severe arthritis (ankylosis detected on flex-
ion, and severely impaired movement) [21].
Histologic examinations
The whole ankle joints harvested from the right side of each
mouse were fixed overnight in 10% formalin, decalcified in
30% citrate-buffered formic acid for 3 days at 4°C, dehy-
drated in a graded series of methanol and xylene, and then
embedded in paraffin. Thin sections (6 µm thick) were
stained with hematoxylin and eosin, and histopathologic
scorings performed under the light microscope (Leitz Aris-
toplan) by a blinded observer. The histopathologic score
(HS) was evaluated [21] using a scale of severity ranging
from 1 to 4, where 1 = hyperplasia of the synovial mem-
brane and presence of polymorphonuclear infiltrates, 2 =
pannus and fibrous tissue formation and focal subchondral
bone erosion, 3 = articular cartilage destruction and bone
erosion, and 4 = extensive articular cartilage destruction
and bone erosion.
Scoring of joint parameters
Arbitrary scores were used to assess the extent of synovi-
tis, cartilage destruction, and bone erosion. Semiquantita-
tive scores from 0 to 4 were used for each histopathologic
parameter [22]. Synovitis: 0 = normal; 1 = mild synovial
hypertrophy (<5 cell layers) with few inflammatory cells; 2
= moderate synovial hypertrophy (<20 cell layers) with
accumulation of inflammatory cells into intrasynovial cysts;
3 = pannus and fibrous tissue formation; and 4 = pannus
and fibrous tissue formation on both sides of the ankle joint.
Cartilage damage: 0 = intact; 1 = minor (<10%); 2 = mod-
erate (10–50%); 3 = high (50–80%); and 4 = severe (80–
100%). Bone erosions: 0 = normal; 1 = mild (focal
subchondral erosion); 2 = moderate (multiple subchondral
erosions); 3 = high (as above + focal erosion of talus); and
4 = maximum (multiple erosions of tarsal and metatarsal
bones).
Transmission electron microscopy
Ankle joints dissected from the left hind leg of each mouse
were split open longitudinally through the midline between
the tibia and the talus, prefixed overnight with 2.5% glutar-
aldehyde in phosphate buffer, pH 7.4, and rinsed with the
buffer. After they had been postfixed with 1% osmium
tetroxide in phosphate buffer for 2 hours, they were dehy-
drated in a graded series of ethanol and embedded in
epoxy resin (Araldite). Semithin sections (1.0 µm) were cut
and stained with methylene blue to reveal their orientation
for ultrathin sectioning and for histopathologic scoring
under the light microscope. Ultrathin sections (80–90 nm)
were then cut with an ultramicrotome (Ultracut E; Riechert-
Jung, Leica, Vienna, Austria), mounted on copper grids,
counterstained with uranyl acetate and lead citrate, and
evaluated in the electron microscope (CM120 Biotwin; FEI
Company, Electron Optics, Eindhoven, The Netherlands).
Measurement of serum PLA2
sPLA2 was measured in the serum of transgenic (Tg197)
mice and nontransgenic wild-type controls, using an
Escherichia coli membrane assay as described previously
[18]. In brief, [3H]arachidonate-labeled E. coli membrane
suspension (5.8 µCi/µmol, PerkinElmer Life Sciences, Inc,
Boston, MA, USA) was used as substrate, and 25 mM
CaCl2- 1 0 0  m M  T r i s / H C l  ( p H  7 . 5 )  a s  a s s a y  b u f f e r .  T h e
reaction mixture, containing substrate (20 µl) and either
purified human synovial sPLA2 standard (1–80 ng/ml; Cay-
man Chemical Company, Ann Arbor, MI, USA) or serum
(10 µl), in a final volume of 250 µl in assay buffer, was incu-
bated at 37°C for 1 hour, and the reaction was terminated
with 750 µl of chilled phosphate-buffered saline containing
1% bovine serum albumin. Aliquots (500 µl) of the super-
natant were then taken, for measurement of the amount of
[3H]arachidonate released from the E. coli membrane
using liquid scintillation counting (LS 6500 Scintillation
Counter; Beckman Inc., Fullerton, CA, USA). The amount of
sPLA2 present in the serum was calculated from the stand-
ard curve and is expressed as ng/ml ± SEM.
Cell culture
The murine macrophage cell line J774 (American Type Cul-
ture Collection, Manassas, VA, USA) was cultured at 37°C
in humidified 5% CO2/95% air in Dulbecco's modified
Eagle's medium containing 10% fetal bovine serum, 2 mM
glutamine, 20 mM HEPES, 100 IU/ml penicillin, and 100
µg/ml streptomycin. After growing to confluence, the cells
were dislodged by scraping, plated in 12 culture wells at a
density of 5 × 105 cells/ml per well, and allowed to adhere
for 2 hours. Thereafter, the medium was replaced with fresh
medium containing lipopolysaccharide (LPS) (2 µg/ml) and
one of the PLA2 inhibitors (P-NT.II, scrambled P-NT.II, or
LY315920 [Lilly Research Laboratories, Indianapolis, IN,
USA], dissolved in DMSO [final concentration 0.1% v/v]).
Peptides were tested at various concentrations ranging
from 0.01 to 40 µM. After incubation in 5% CO2/95% air
at 37°C for 20 hours, culture medium supernatants were
collected and stored frozen (-80°C) until use. In parallel
experiments, cells were stimulated with mouse recom-
binant TNF (10 ng/ml; Sigma, St. Louis, MO, USA) for 20
hours, in the presence or absence of 10 µM P-NT.II or
LY315920 dissolved in DMSO (0.1% final concentration).
Culture medium supernatants were collected after centrifu-
gation (10,000 g, 4°C, 15 min) and stored at -80°C prior to
measurement of prostaglandin E2 (PGE2).
Cell viability assays
XTT (sodium 3'-[(phenyl amine carboxyl)-3,4-tetrazolium]-
bis(4-methoxy-nitro) benzene sulfonic acid hydrate) Cell
Proliferation Kit II (Roche Applied Science) was used to
assess the possible cytoxic effect of the peptide P-NT.II on
the mouse macrophage J774 cell line.Arthritis Research & Therapy    Vol 6 No 3    Thwin et al.
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Measurement of PGE2
PGE2 (EIA kit-monoclonal; Cayman) concentrations were
measured in the cell-culture supernatants in accordance
with the manufacturer's instructions.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
software to calculate the means and SEMs. Group means
were compared by using one-way analysis of variance
(ANOVA), followed by Bonferroni's multiple comparison




Figure 1 shows the histologic features of ankle joints of
Tg197 mice in the untreated, P-NT.II-treated, and scram-
bled-P-NT.II-treated groups. Gross histologic findings of
the three experimental groups are summarized in Table 1.
At 8 weeks of age, ankle joints from the untreated Tg197
group were moderately (90% with HS 3) to severely (10%
with HS 4) damaged, with pannus and fibrous tissue forma-
tion and focal subchondral bone erosion. Articular cartilage
destruction and bone erosion were observed in 90% of
those joints (Fig. 1a,1b). In contrast, all the articular carti-
lage surfaces and associated synovial linings of the ankle
joints of the P-NT.II-treated group at 2 weeks post-treat-
ment (i.e. age 6 weeks) were only mildly affected (HS 2),
with no evidence of cartilage or bone erosion (Fig. 1c), and
25% of joints were affected moderately (HS 3) at 4 weeks
post-treatment (i.e. age 8 weeks) (Fig. 1d). In contrast,
83.3% of joints of scrambled-P-NT.II-treated Tg197 mice
at 8 weeks of age were moderately damaged (HS 3) (Fig.
1e,1f), with histologic features similar to those of the
untreated Tg197 mice. Although the disease, as assessed
by the HS, was significantly lower in the P-NT.II-treated
group than in the untreated or scrambled-P-NT.II-treated
groups, visual disease scores (ASs) did not correlate well
with the HS. In contrast to HSs, ASs of mice treated with
P-NT.II did not significantly differ from those of the
untreated or scrambled-P-NT.II-treated group (Fig. 2).
Analytical HS
To assess specific effects of the peptide P-NT.II on synovi-
tis, cartilage destruction, and bone erosion, we conducted
a semiquantitative scoring analysis for each of these path-
ologic parameters. P-NT.II treatment in Tg197 mice
resulted in a significant reduction (P < 0.05) in all three
analytical HSs as compared with those of untreated or
scrambled-P-NT.II-treated Tg197 mice, which all devel-
oped synovitis with severe articular cartilage degradation
and bone erosions (Fig. 3). Statistical analysis revealed a
greater beneficial effect of P-NT.II on cartilage destruction
and bone erosion (**P < 0.01 versus untreated or scram-
bled-P-NT.II-treated groups for both parameters) than on
synovitis (*P < 0.05 versus untreated or scrambled-P-NT.II-
treated groups).
Ultrastructural changes in articular cartilage
Articular cartilage in the ankle joints of all untreated Tg197
mice was generally damaged at 8 weeks of age (Fig.
4c,4d,4e,4f) as compared with normal morphology seen in
control, wild-type mice (Fig. 4a). No significant ultrastruc-
tural changes in the nucleus and plasma membrane were
noted at the cellular level in the articular cartilage of
untreated Tg197 mice at age 4 weeks (baseline) except for
some minor changes including vacuoles, dilated cisternae,
and the presence of granular materials seen inside the
cytoplasm (Fig. 4b). In the 8-week-old mice, the chondro-
cytes on the surface of the superficial cartilage layer had
become necrotic, with alterations of cartilage developed in
most cases (Fig. 4c,4d,4e,4f). The cell body and nucleus of
some chondrocytes became large and rounded, resulting
in vacuolation, and the cytoplasm was transparent, with an
accumulation of intracytoplasmic filaments (Fig. 4c).
Degenerating chondrocytes with greatly vacuolated cyto-
plasm and pyknotic nuclei (Fig. 4d), and chondrocytes with
complete loss of nuclei and disrupted rough endoplasmic
reticulum (r-ER) (Fig. 4e,4f), were also observed. In con-
trast, the ultrastructural features of chondrocytes 1–4
weeks after P-NT.II treatment (i.e. age 5–8 weeks; Fig. 5a)
did not substantially differ from those seen in the joints of
normal wild-type mice (Fig. 4a). Most of them had a promi-
nent nucleus, lined by plasma membrane with short cyto-
plasmic protrusions, and vacuoles, r-ER, and mitochondria
in the cytoplasm. The ultrastructure of chondrocytes of the
scrambled-P-NT.II-treated joints at 8 weeks of age (Fig. 5b)
were more or less similar to those described for untreated
Tg197 mice with degenerating features such as the greatly
vacuolated cytoplasm and pyknotic nuclei (cf. Fig. 4d) or
loss of nucleus, disrupted r-ER (cf. Fig. 4f), and swollen
mitochondria with distorted cristae (cf. Fig. 4c).
Ultrastructural changes in synovium
The early response of the synovial membrane in the
untreated Tg197 mice at age 4 weeks (baseline) was syn-
ovial hyperplasia, with the presence of type A and B syno-
vial cells along with inflammatory cells such as
lymphocytes, macrophages, and mast cells. Type A cells
were similar to macrophage cells and were characterized
by many vesicles, vacuoles, and a higher number of cell
processes. Type B cells were similar to fibroblast cells and
contained small vesicles and r-ER. The later response (at ≥
5 weeks of age) included degeneration of synovial cells,
with swollen mitochondria and cell fragmentations. In areas
of high inflammation, the synovial tissue (mostly type A
cells) had proliferated into the articular cavity (Fig. 6a). Type
A and B cells in the synovium were no longer distinguisha-
ble at age 6 weeks and thereafter. The synovial membrane
was lined by closely packed elongated synoviocytes whichAvailable online http://arthritis-research.com/content/6/3/R282
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Figure 1
Histologic findings in the ankle joints of Tg197 mice Histologic findings in the ankle joints of Tg197 mice. (a,b) Untreated mice: (a) partially altered articular cartilage (crt) with bone erosion (arrowhead), 
and presence of inflammatory infiltrates (arrow) in the synovial (syn) tissue; (b) extensive articular cartilage destruction and bone erosion (arrow-
head). (c,d) P-NT.II-treated mice: (c) minor cartilage changes (crt) with absence of bone erosion; (d) focal articular cartilage destruction (crt) and 
minor bone erosion (arrowhead). (e,f) Mice treated with scrambled P-NT.II: (e) the joint cavity (jc) is lined with synovitis (*); (f) cartilage destruction 
and bone erosion (arrowhead) are present, along with inflammatory infiltrates (arrow). Nontransgenic controls showed normal joint structures 
throughout the study (data not shown). (Hematoxylin & eosin staining; original magnification ×25 in a, e, f; ×10 in b, c, d. Bars = 500 µm).Arthritis Research & Therapy    Vol 6 No 3    Thwin et al.
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were sealed by junctional systems of the adherent type
(Fig. 6b). Large amounts of fibrin deposition on the synovial
surface could be seen, and the two opposing, flattened
synoviocytes with fibrin between them indicated the exist-
ence of synovial adhesion (Fig. 6d). Also, degenerating syn-
oviocytes with disintegrating nuclei and vacuolated
cytoplasm were randomly seen in the synovium (Fig. 6c).
Synoviocytes appeared flattened, and partially degranu-
lated mast cells were seen under the synovium (Fig. 6e).
P-NT.II treatment tended to decrease the number of inflam-
matory cells, with less degeneration of synovial cells and
cell fragmentation seen in the joints of the treated group
(Fig. 7b). The peptide P-NT.II retained at least the basic
structural organization of the synovial membrane seen in
the control wild-type mice (Fig. 7a), while the synoviocytes
from mice treated with scrambled P-NT.II (Fig. 7c) were
structurally indistinguishable from those seen in untreated
joints (cf. Fig. 6). In those joints, the synovial cells were
seen lining up close together, and many cell fragments
resulting from degenerating cells were present in the syn-
ovium, along with infiltrating mast cells (Fig. 7c).
Serum levels of sPLA2
In a time-course study to evaluate the specific effect of pep-
tide in modulating the serum sPLA2 levels in Tg197 mice
(Fig. 8), P-NT.II significantly suppressed the circulating
sPLA2 in the mice at age 8 weeks (P < 0.05), by compari-
son with the serum levels of the untreated mice of same
age. In contrast, the circulating sPLA2 of scrambled-P-NT.II-
treated and untreated Tg197 mice at age 8 weeks were not
significantly different (P > 0.05), thus indicating the spe-
cific effect of the peptide P-NT.II on sPLA2 levels.
PGE2 release from cultured macrophages
The suppressive effect of P-NT.II and sPLA2-selective
inhibitor LY315920 (Lilly) on LPS- and TNF-stimulated
PGE2 production was examined in mouse macrophage cell
cultures (Fig. 9). Production of PGE2  in the medium
increased approximately sixfold from the basal level of 55 ±
6 pg/ml to 320 ± 35 and 330 ± 11 pg/ml (mean ± SD, N
= 5), after 20 hours' stimulation of cultured cells with LPS
(2 µg/ml) (Fig. 9a) or TNF (10 ng/ml) (Fig. 9b), respectively.
When the inhibitors were coincubated with either LPS- or
TNF-stimulated macrophages in the medium, both P-NT.II
and LY315920 (final concentration 10 µM) dose-depend-
ently inhibited PGE2 production, with estimated IC50 values
of 25 and 30 µM, respectively. In contrast, scrambled P-
NT.II (negative control) showed no inhibitory effect on
either LPS- or TNF-induced PGE2 release in the culture
medium. Neither the peptide nor LY315920 affected the
cellular viability, when tested by XTT assay kit at the highest
concentration (40 µM) used in culture experiments (E492 nm
values of 0.89 ± 0.02, 0.84 ± 0. 021, and 0.92 ± 0.019 for
untreated, P-NT.II-treated, and LY315920-treated cells,
respectively).
Discussion
Here we report the beneficial effect of peptide treatment,
and the ultrastructural changes seen at the cellular level in
the articular cartilage and synovium of the ankle joints of
TNF transgenic Tg197 mice treated with the anti-inflamma-
tory peptide P-NT.II. While several studies have previously
been carried out on the early ultrastructural changes in
other animal models of experimental arthritis [23-25], no
morphological evaluations in this TNF transgenic mouse
model of RA have yet been available, in either the absence
or the presence of therapeutic intervention.
Table 1
Histopathologic assessment of ankle joints
% of total at indicated HS
Treatment Time course (weeks) Joints scored HS 2 HS 3 HS 4 HS (Mean ± SEM)
None 4 10 0 90.0 10 3.30 ± 0.11a
P-NT.II* 1 4 100 0 0 2.12 ± 0.12
P-NT.II* 2 4 100 0 0 2.37 ± 0.12
P-NT.II* 3 4 75 25 0 2.50 ± 0.20
P-NT.II* 4 4 75 25 0 2.62 ± 0.31b
Scrambled-P-NT.II-treated (negative control peptide) 4 6 16.7 83.3 0 3.25 ± 0.17c
*Tg197 mice injected (intraperitoneally) with the test peptide P-NT.II were killed at weekly intervals (N = 4 per group) for 4 weeks and their ankle 
joints examined. For untreated and negative control groups, ankle joints were harvested only at the end of the 4 weeks' study course for one-time 
examination. Histologic scoring was performed semiquantitatively by a blinded examiner. HS 2 = pannus and fibrous tissue formation and focal 
erosion of subchondral bone; HS 3 = articular cartilage destruction and bone erosion; HS 4 = extensive articular cartilage destruction and bone 
erosion. a versus b, b versus c = significantly different (P < 0.05; one-way analysis of variance with Bonferroni's multiple comparison test). HS, 
histopathologic score; SEM, standard error of the mean.Available online http://arthritis-research.com/content/6/3/R282
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The lesions in the TNF transgenic mouse model of arthritis
we used in the present study histologically and ultrastruc-
turally resemble RA lesions [26], with synovial proliferation
along the articular surface and subsequent invasion with
erosion of the articular cartilage and subchondral bone.
Although visual disease scores (ASs) did not show any sig-
nificant difference between P-NT.II-treated and control
(scrambled-P-NT.II-treated or untreated) groups, the
results obtained from gross histologic analysis (Table 1)
and semiquantitative analysis of pathologic parameters
(Fig. 3) clearly demonstrate the beneficial effect of peptide
treatment in preventing synovitis, cartilage destruction, and
bone erosion. Similar discrepancies between AS and HS
have also been reported in TNF-transgenic and other
experimental models of arthritis. Redlich and colleagues
[27] recently reported a protective effect of osteoprote-
gerin treatment on bone damage in Tg197 mice, with lack
of any beneficial effect on the clinical symptoms. In another
experimental model of passive collagen-induced arthritis
using JNK2-deficient mice, it has been shown that clinical
symptoms appear to be slightly more severe than HS
despite significant reductions in joint destruction due to
preservation of the articular cartilage [28]. It seems, there-
fore, that preservation of the bone structure may not always
correlate with the clinical symptoms. The striking difference
observed in the ultrastructural features of the articular
cartilage and synovial membrane in our animal model
before and after peptide treatment did confirm that P-NT.II
administered as an exogenous drug in this TNF transgenic
mouse model of RA was able to improve the overall mor-
phology and the cellular component of the synovium, and of
the cartilage in particular.
Ultrastructural changes of ankle articular cartilage and syn-
ovium in Tg197 mice were evaluated using transmission
electron microscopy, before and during the 4-week course
of treatment. Histologically, we observed an apparent sup-
pression of pannus formation and minimal erosive damage
to the articular cartilage and subchondral bone. At 1–4
weeks post-treatment with peptide (i.e. at age 5–8 weeks),
the number of inflammatory cells in the synovial tissue was
reduced as early as 1 week after initiation of treatment, and
the structural organization of the synovial membrane of the
ankle joint appeared less modified. In the P-NT.II-treated
group, lesions such as synovial adhesions, cell fragmenta-
tion due to degeneration of synoviocytes, and dilation of the
r-ER and distorted cristae of type B cells were less obvious
than in the untreated or scrambled-P-NT.II-treated groups.
In our cell-culture experiments using mouse macrophages,
P-NT.II has been found to dose-dependently inhibit LPS- or
TNF-induced PGE2 production, with a potency equal to
that of a potent and selective sPLA2 inhibitor, LY315920
[29]. It is possible that P-NT.II may modulate ultrastructural
modifications to the synovium by reducing the bioavailabil-
ity of arachidonic acid (AA) through sPLA2 inhibition, and
Figure 2
The arthritis score (AS) in Tg197 mice changes with time course The arthritis score (AS) in Tg197 mice changes with time course. The 
AS was determined on both ankle joints of each mouse by a blinded 
examiner, using a scale of 0–3 as described in Materials and methods. 
Values are the mean ± SEM.
Figure 3
Histopathologic score (HS) analysis of various histopathologic parame- ters in Tg197 mice Histopathologic score (HS) analysis of various histopathologic parame-
ters in Tg197 mice. Synovitis, cartilage degradation, and bone erosion 
were semiquantitatively assessed in the ankle joints of Tg197 mice that 
were untreated, treated with P-NT.II, or treated with scrambled-P-NT.II 
(N = 4/group) at 4 weeks post-treatment (i.e. age 8 weeks). The HS 
indicates a protective effect of P-NT.II in all three histopathologic 
parameters of arthritis. Statistical analysis revealed a greater beneficial 
effect of P-NT.II on cartilage destruction and bone erosion (**P < 0.01 
versus untreated or scrambled-P-NT.II-treated groups for both parame-
ters) than on synovitis (*P < 0.05 versus untreated or scrambled-P-
NT.II-treated groups).Arthritis Research & Therapy    Vol 6 No 3    Thwin et al.
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Figure 4
Chondrocytes of wild-type controls and untreated Tg197 mice Chondrocytes of wild-type controls and untreated Tg197 mice. (a) Wild-type control at age 8 weeks: nucleus (N), plasma membrane with short 
cytoplasmic protrusions (arrow), rough endoplasmic reticulum (r-ER) (arrowhead), and mitochondria (m); (b) untreated Tg197 mouse at age 4 
weeks: nucleus (N) and plasma membrane with cytoplasmic thin protrusions (arrow) appear normal, while the cytoplasm shows vacuoles (v) with 
granular materials inside (double arrow) and dilated cisternae (arrowhead). (c-f) Untreated Tg197 mouse at age 8 weeks: degenerating chondro-
cytes showing the following: (c) transparent cytoplasm with nucleus (N) and an accumulation of intracytoplasmic filaments (f), vacuoles (v) and mito-
chondria (m) with distorted cristae; (d) greatly vacuolated cytoplasm (v), and pyknotic nuclei (N) with cytoplasmic projections coming apart from the 
cell (arrow); (e) cell organelles from disintegrated cells (o), mitochondria (m), bundles of densely packed collagen fibres (arrowhead), small residues 
of intermediate filaments (f), and broken cellular processes (arrow); (f) swollen and disrupted r-ER, and bundles of thickened intermediate filaments 
(f). Basement membrane, cytoplasmic organelles (arrow), and cellular processes (arrowhead) were also fragmented. Electron-dense areas (e) are 
seen in the intercellular matrix. N = 4 joints; mean percentage of degenerating chondrocytes = 40% and 80% of total at 4 and 8 weeks of age, 
respectively. Bars = 2 µm.Available online http://arthritis-research.com/content/6/3/R282
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suppress the severity of the prostaglandin-mediated inflam-
matory response in the synovium.
The ultrastructural features of the articular cartilage
observed in this human TNF transgenic mouse model of RA
suggest that the chondrocyte may be one of the important
targets of the peptide intervention in modulating the pro-
gression of the joint erosion. Our extensive histopathologic
analysis of joints in the Tg197 TNF model in this study (Fig.
3) has revealed both articular cartilage destruction and
subchondral bone erosion at the advanced stages of dis-
ease (i.e. 8 weeks of age). Similar severe cartilage destruc-
tion in Tg197 mice at 7–8 weeks of age has previously
been shown as evidenced by the loss of safranin-O staining
[22]. Massive cartilage and subchondral bone erosion in
the joints is the hallmark of inflammatory arthritis in the TNF
transgenic mouse model [30]. At 3–4 weeks post-treat-
ment (i.e. at 7–8 weeks of age), P-NT.II significantly
reduced chondrocyte necrobiosis, which was frequently
seen in the proximity of invading synovium in untreated con-
trols at same age. It is possible that sPLA2  might be
involved in cartilage destruction in the TNF-transgenic
model. sPLA2 found in the synovial fluid has been reported
to originate from chondrocytes and not from the synovial
lining or inflammatory cells [31]. Human articular chondro-
cytes synthesize and constitutively release sPLA2, and are
therefore suggested to be responsible for the high concen-
tration of sPLA2 present in articular cartilage [32]. cPLA2 is
also reported to be involved in PGE2 production by osteob-
last cells [33], while there are reports indicating that sPLA2
augments cPLA2  expression in mouse osteoblasts via
endogenous PGE [13,34]. Because of the significant func-
tional coupling and/or synergism that can exist between
cPLA2  and sPLA2  in various cells [3,13,33-35], sPLA2
could conceivably be involved in chondrocyte destruction
in RA by playing a role in bone resorption through crosstalk
with cPLA2.
We have found significantly elevated levels of circulating
sPLA2 in Tg197 mice at 8 weeks of age as compared with
the much lower baseline levels detected at 4 weeks of age.
Elevated levels of sPLA2 have been reported in the plasma
of patients with acute and chronic inflammatory diseases
[36]. sPLA2 can mobilize AA to induce the de novo synthe-
sis of eicosanoids in a variety of inflammatory cells [37],
leading to subsequent release of proinflammatory
mediators. Recently, sPLA2 has been shown to amplify
TNF-induced PGE2  synthesis in human rheumatoid
synoviocytes [8], a process that is blocked by cyclic pep-
tide inhibitors of human sPLA2 [38]. The use of a low-
molecular-weight peptide, such as P-NT.II, that effectively
lowers sPLA2 could be of clear clinical benefit in similar sit-
uations. Our results obtained with P-NT.II-treated Tg197
mice demonstrated that this new peptide inhibitor signifi-
cantly suppressed the circulating sPLA2 activity in those
mice, whereas scrambled P-NT.II (negative control pep-
tide) was without any effect.
Figure 5
Chondrocytes of treated Tg197 mice Chondrocytes of treated Tg197 mice. (a) Chondrocytes of P-NT.II-
treated Tg197 mice at 5–8 weeks of age (i.e. 1–4 weeks post-treat-
ment) were similar to those described for normal chondrocytes, with 
almost intact nucleus (N), basement membrane (arrowhead), and cyto-
plasmic organelles – vacuoles (v), rough endoplasmic reticulum (r-ER), 
mitochondria (m); (b) Most chondrocytes of Tg197 mice treated with 
scrambled P-NT.II at age 8 weeks (i.e. 4 weeks post-treatment) were 
degenerated, with vacuolated cytoplasm (v), a disrupted Golgi complex 
(g), pyknotic nuclei (N) with a well-defined, enlarged perinuclear space 
(arrows), and cytoplasmic projections broken from the cell (arrowhead). 
N = 4 joints/group; mean percentage of degenerating chondrocytes at 
age 8 weeks = 20% and 75% of total in (a) and (b), respectively. Bars 
= 2 µm.Arthritis Research & Therapy    Vol 6 No 3    Thwin et al.
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Figure 6
Synovium of untreated Tg197 mice at age 8 weeks Synovium of untreated Tg197 mice at age 8 weeks. (a) Proliferation of the synovial tissue (syn) in the articular cavity (ac) showing macrophage-like 
type A synoviocytes (sa) with thin cytoplasmic protrusions (arrow) invading the articular surface (as), and closely packed secretory type B synovio-
cytes (sb) seen in the superficial layer of pannus. (b) The synovial membrane was lined by closely packed, elongated (arrow) or rounded synovio-
cytes with infiltrating cells (arrowhead) present under the synovium. (c) Degenerating synoviocyte with disintegrated nuclei (arrow) and vacuolated 
(v) cytoplasm along with disrupted collagen fibres (arrowhead) randomly seen in the synovium. (d) Adherent-type junction (arrow) sealing two syn-
oviocytes with fibrin (f) between them. (e) Synoviocytes appeared flattened, and partially degranulated mast cells (arrow) are seen under the syn-
ovium. N = 4 joints; mean percentage of degenerating synoviocytes = 80% of total cells. Bars = 5 µm. c, chondrocytes; N, nucleus.Available online http://arthritis-research.com/content/6/3/R282
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The data obtained from the present study suggest that P-
NT.II ameliorates synovitis and bone and cartilage erosions
in the joints through modulation of circulatory and localized
sPLA2, which might otherwise amplify TNF-dependent
pathways in rheumatoid synovium. Although the mode of
action of sPLA2 in this animal model is not exactly known,
the potential mechanism may involve binding to a receptor
[39], followed by internalization [40] and transfer of sPLA2
to intracellular pools of phospholipids enriched in AA [41].
Further catalysis by sPLA2 through surface interactions can
then initiate and promote pathology by releasing AA, which
can subsequently be converted to proinflammatory pros-
taglandins and leukotrienes. There are no published reports
of sPLA2 inhibitors showing benefit on bone erosion. The
ultrastructural evidence of the beneficial effect of the pep-
tide on joint destruction as shown here suggests a possible
use of sPLA2 inhibitors in the treatment of inflammatory
bone loss diseases such as RA. However, some caution is
advisable in the interpretation of the findings, since the
nature of the arthritis in a purely TNF-driven disease, such
as that observed in TNF transgenic mice, may not truly
reflect the situation in human inflammatory joint diseases.
Conclusion
The present study provides ultrastructural demonstration of
the modulatory effect of the P-NT.II peptide on synovial
Figure 7
Synovium of treated Tg197 mice Synovium of treated Tg197 mice. (a) Nontransgenic wild-type group 
(control) at age 8 weeks: type A (sa) and type B (sb) synoviocytes are 
arranged loosely in the synovium (syn). Type A cells are characterized 
by many thin filopodia (arrow), while type B cells contain many 
instances of rough endoplasmic reticulum (r-ER), small vesicles, and 
basement membrane structures (arrowhead); (b) P-NT.II-treated Tg197 
group at 5–8 weeks of age: synoviocyte A cells (sa) with characteristic 
cytoplasmic processes intermingled with those of neighboring cells 
(arrow) and B cells (sb), seen at age 6–8 weeks of age (i.e. 2–4 weeks 
post-treatment), appear unmodified during the time course (1–4 weeks) 
of treatment. The ultrastructural features are similar to those seen in the 
ankle joints of wild-type controls in (a). (c) Scrambled-P-NT.II-treated 
Tg197 group at age 8 weeks: type A (sa) and B (sb) synovial cells were 
seen lining up close together, and many cell fragments (arrowheads) 
resulting from fibrous degeneration of endothelial cells were present in 
the synovium (syn), along with infiltrating mast cells (arrows). N = 4 
joints/group; mean percentage of degenerating synoviocytes = 24% 
and 75% of total in (b) and (c), respectively. Bars = 2 µm.
Figure 8
Time course of serum phospholipase A2 (sPLA2) levels Time course of serum phospholipase A2 (sPLA2) levels. Serum sPLA2 
levels were measured with an Escherichia coli membrane assay in 
blood samples collected from untreated, P-NT.II-treated, and scram-
bled-P-NT.II-treated Tg197 mice at weekly intervals during the 4 weeks' 
time course of treatment. Values are the mean ± SD (N = 4/group). 
One-way ANOVA with Bonferroni's multiple comparison post test: P < 
0.05, untreated versus P-NT.II-treated (age 8 weeks); P < 0.05, scram-
bled-P-NT.II-treated versus P-NT.II-treated (age 8 weeks).Arthritis Research & Therapy    Vol 6 No 3    Thwin et al.
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inflammation and joint destruction in TNF-driven Tg197
mouse model of human RA. The results suggest that sPLA2
seems to play a significant role in inflammatory arthritis, and
sPLA2 inhibitors may be useful for the development of novel
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